In addition to our founding investors, PrimeGen is interested in partnering with experienced and vetted early-stage healthcare and life science investors. For more information about our progress and plans, please fill out the inquiry form below.
PrimeGen US follows an agile model for the development of novel therapies. Whether it is in the development of clinical grade FDA-approved stem cells or the rapid design, execution or analysis of clinical research, PrimeGen contracts and collaborates with the industry’s most reliable resources.
USC is PrimeGen’s premier research partner for the development of stemXcell treatments for liver disease models.
PrimGen US is an exclusive licensee of stem cell activation patents held by Rutgers University.
Rooster Bio is the supplier of raw biomaterials used in the development of PrimeGen US cellular therapies.
PrimeGen is committed to the highest scientific and ethical standards for publications and is dedicated to providing scientifically accurate, fair, and well-balanced publications to the scientific community.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. PrimeGen US, Inc. makes no representation and assumes no responsibility for the accuracy of information contained on or available through this web site, and such information is subject to change without notice. You are encouraged to confirm any information obtained from or through this web site with other sources, and review all information regarding any medical condition or treatment with your physician.
NEVER DISREGARD PROFESSIONAL MEDICAL ADVICE OR DELAY SEEKING MEDICAL TREATMENT BECAUSE OF SOMETHING YOU HAVE READ ON OR ACCESSED THROUGH ANY WEB SITE.